To verify whether Raf1‐Pkm2 could be clinically translated in the treatment of other cancers, we determined the effect of Raf1 and Pkm2 gene pairs on the survival rate of other tumours in the TCGA database and observed that the Raf1 and Pkm2 gene pairs were related to two other cancers, thymoma (THYM) and lung adenocarcinoma (LUAD), showing favourable clinical efficacy compared to single‐gene knockout (Figure S8B and C). Here, PKM is linked to lung adenocarcinoma.